Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 18c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.83), $0.18 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $37.96 million versus the consensus estimate of $27.13 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• Fidelity National Financial (FNF) spreader of 3K contracts of October 35, October 45, November 30 and November 35 puts
• Black Hills Corp. (BKH) 3500 contracts of October 80 calls active, share price up 2.5%